• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Type o Market segments o Comparison by Type o Corticosteroids - Market size and forecast 2019-2024 o Xanthine derivatives - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Type • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Volume drivers – External factors o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Cadila Healthcare Ltd. o Dr. Reddy's Laboratories Ltd. o Gilead Sciences Inc. o Johnson & Johnson o Mylan NV o Novartis AG o Sanofi o Sun Pharmaceutical Industries Ltd. o Takeda Pharmaceutical Co. Ltd. o Teva Pharmaceutical Industries Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Type - Market share 2019-2024 (%) • 22: Comparison by Type • 23: Corticosteroids - Market size and forecast 2019-2024 ($ million) • 24: Corticosteroids - Year-over-year growth 2019-2024 (%) • 25: Xanthine derivatives - Market size and forecast 2019-2024 ($ million) • 26: Xanthine derivatives - Year-over-year growth 2019-2024 (%) • 27: Others - Market size and forecast 2019-2024 ($ million) • 28: Others - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Type • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: Asia - Market size and forecast 2019-2024 ($ million) • 38: Asia - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: Cadila Healthcare Ltd. - Overview • 50: Cadila Healthcare Ltd. - Business segments • 51: Cadila Healthcare Ltd. - Key offerings • 52: Cadila Healthcare Ltd. - Key customers • 53: Cadila Healthcare Ltd. - Segment focus • 54: Gilead Sciences Inc. - Overview • 55: Gilead Sciences Inc. - Product and service • 56: Gilead Sciences Inc. - Key offerings • 57: Gilead Sciences Inc. - Key customers • 58: Gilead Sciences Inc. - Segment focus • 59: Johnson & Johnson - Overview • 60: Johnson & Johnson - Business segments • 61: Johnson & Johnson - Key offerings • 62: Johnson & Johnson - Key customers • 63: Johnson & Johnson - Segment focus • 64: Mylan NV - Overview • 65: Mylan NV - Business segments • 66: Mylan NV - Key offerings • 67: Mylan NV - Key customers • 68: Mylan NV - Segment focus • 69: Novartis AG - Overview • 70: Novartis AG - Business segments • 71: Novartis AG - Key offerings • 72: Novartis AG - Key customers • 73: Novartis AG - Segment focus • 74: Sanofi - Overview • 75: Sanofi - Business segments • 76: Sanofi - Key offerings • 77: Sanofi - Key customers • 78: Sanofi - Segment focus • 79: Sun Pharmaceutical Industries Ltd. - Overview • 80: Sun Pharmaceutical Industries Ltd. - Business segments • 81: Sun Pharmaceutical Industries Ltd. - Key offerings • 82: Sun Pharmaceutical Industries Ltd. - Key customers • 83: Sun Pharmaceutical Industries Ltd. - Segment focus • 84: Takeda Pharmaceutical Co. Ltd. - Overview • 85: Takeda Pharmaceutical Co. Ltd. - Product and service • 86: Takeda Pharmaceutical Co. Ltd. - Key offerings • 87: Takeda Pharmaceutical Co. Ltd. - Key customers • 88: Takeda Pharmaceutical Co. Ltd. - Segment focus • 89: Teva Pharmaceutical Industries Ltd. - Overview • 90: Teva Pharmaceutical Industries Ltd. - Business segments • 91: Teva Pharmaceutical Industries Ltd. - Key offerings • 92: Teva Pharmaceutical Industries Ltd. - Key customers • 93: Teva Pharmaceutical Industries Ltd. - Segment focus • 94: Currency conversion rates for US$ • 95: Research Methodology • 96: Validation techniques employed for market sizing • 97: Information sources • 98: List of abbreviations

Cadila Healthcare Ltd., Gilead Sciences Inc., Johnson & Johnson, Mylan NV, Novartis AG, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.